WO2007131092A3 - Chimeric t cell receptors and related materials and methods of use - Google Patents

Chimeric t cell receptors and related materials and methods of use Download PDF

Info

Publication number
WO2007131092A3
WO2007131092A3 PCT/US2007/068113 US2007068113W WO2007131092A3 WO 2007131092 A3 WO2007131092 A3 WO 2007131092A3 US 2007068113 W US2007068113 W US 2007068113W WO 2007131092 A3 WO2007131092 A3 WO 2007131092A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tcr
chimeric
host
tcrs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/068113
Other languages
French (fr)
Other versions
WO2007131092A2 (en
Inventor
Richard A Morgan
Cyrille J Cohen
Steven A Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38668547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007131092(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA002651174A priority Critical patent/CA2651174A1/en
Priority to AU2007248019A priority patent/AU2007248019B2/en
Priority to EP07797329A priority patent/EP2016102B1/en
Priority to DK07797329.5T priority patent/DK2016102T3/en
Priority to AT07797329T priority patent/ATE550356T1/en
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Priority to ES07797329T priority patent/ES2382777T3/en
Priority to US12/298,927 priority patent/US20090304657A1/en
Publication of WO2007131092A2 publication Critical patent/WO2007131092A2/en
Publication of WO2007131092A3 publication Critical patent/WO2007131092A3/en
Anticipated expiration legal-status Critical
Priority to US13/667,036 priority patent/US20130116167A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a non-human TCR, as well as functional variants thereof. The invention also provides polypeptides and proteins related to the inventive TCRs, as well as nucleic acids encoding the TCRs, polypeptides, or proteins, recombinant expression vectors, and host cells. Further provided are pharmaceutical compositions related to the inventive TCRs and methods of preventing or treating a disease, e.g., an infectious disease, cancer, in a host, methods of detecting a diseased cell in a host, and methods of improving the biological activity of a TCR.
PCT/US2007/068113 2006-05-03 2007-05-03 Chimeric t cell receptors and related materials and methods of use Ceased WO2007131092A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
US12/298,927 US20090304657A1 (en) 2006-05-03 2007-05-03 Chimeric t cell receptors and related materials and methods of use
AU2007248019A AU2007248019B2 (en) 2006-05-03 2007-05-03 Chimeric T cell receptors and related materials and methods of use
EP07797329A EP2016102B1 (en) 2006-05-03 2007-05-03 Chimeric t cell receptors and related materials and methods of use
DK07797329.5T DK2016102T3 (en) 2006-05-03 2007-05-03 Chimeric T cell receptors and associated materials and methods of use
AT07797329T ATE550356T1 (en) 2006-05-03 2007-05-03 CHIMERIC T-CELL RECEPTORS AND CORRESPONDING MATERIALS AND METHODS OF USE
CA002651174A CA2651174A1 (en) 2006-05-03 2007-05-03 Chimeric t cell receptors and related materials and methods of use
ES07797329T ES2382777T3 (en) 2006-05-03 2007-05-03 Chimeric T cell receptor and related materials and methods of use
US13/667,036 US20130116167A1 (en) 2006-05-03 2012-11-02 Anti-mart-1 t cell receptors and related materials and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79685306P 2006-05-03 2006-05-03
US60/796,853 2006-05-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/667,036 Continuation US20130116167A1 (en) 2006-05-03 2012-11-02 Anti-mart-1 t cell receptors and related materials and methods of use

Publications (2)

Publication Number Publication Date
WO2007131092A2 WO2007131092A2 (en) 2007-11-15
WO2007131092A3 true WO2007131092A3 (en) 2008-04-03

Family

ID=38668547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/068113 Ceased WO2007131092A2 (en) 2006-05-03 2007-05-03 Chimeric t cell receptors and related materials and methods of use

Country Status (9)

Country Link
US (2) US20090304657A1 (en)
EP (1) EP2016102B1 (en)
AT (1) ATE550356T1 (en)
AU (1) AU2007248019B2 (en)
CA (1) CA2651174A1 (en)
DK (1) DK2016102T3 (en)
ES (1) ES2382777T3 (en)
PT (1) PT2016102E (en)
WO (1) WO2007131092A2 (en)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (en) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogeneic anti-tumor vaccine with HLA-haplo-identical antigen-presenting cells
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
DE102006041455B4 (en) * 2006-09-04 2011-07-28 Johannes-Gutenberg-Universität Mainz, 55122 A method of producing a cell line stabilized functionalized single-chain human antigen-recognizing TCR (scTCR) expressing cell line, stabilized TAA-specific scTCR, uses thereof, and pharmaceutical compositions containing them
US8088379B2 (en) * 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
WO2009045308A2 (en) * 2007-10-03 2009-04-09 Fred Hutchinson Cancer Research Center Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression
WO2010012829A1 (en) * 2008-07-31 2010-02-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Her2/neu specific t cell receptors
EP2186825A1 (en) * 2008-11-13 2010-05-19 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Human-derived T cell receptors
DK2352756T3 (en) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen High-affinity T cell receptor and its use
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
WO2010088160A1 (en) * 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2010126766A1 (en) 2009-04-30 2010-11-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
GB0917094D0 (en) * 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
CN103124740B (en) * 2010-09-21 2015-09-02 美国卫生和人力服务部 Anti-SSX-2T cell receptor and associated materials and using method
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
CN107858333B (en) * 2011-10-28 2022-05-27 瑞泽恩制药公司 T cell receptor gene modified mice
WO2013169691A1 (en) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
EP2852613B1 (en) 2012-05-22 2019-01-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Murine anti-ny-eso-1 t cell receptors
KR102499753B1 (en) 2012-07-27 2023-02-16 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Engineering t-cell receptors
US10316289B2 (en) 2012-09-06 2019-06-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing T memory stem cell populations
TR201905447T4 (en) 2012-12-14 2019-05-21 Biontech Rna Pharmaceuticals Gmbh New mhc independent tumor associated antigens.
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
US9486475B2 (en) 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (en) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
EP3699190B9 (en) 2013-02-22 2023-10-04 Regeneron Pharmaceuticals, Inc. Murine cell expressing humanized major histocompatibility complex
EP3404111A1 (en) * 2013-03-13 2018-11-21 Health Research, Inc. Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
ES2745472T3 (en) 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Human papillomavirus 16 E6 T-cell receptors
GB201313377D0 (en) 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
EP3083674B1 (en) 2013-12-19 2018-10-03 Friedrich-Alexander-Universität Erlangen-Nürnberg Influenza-specific t-cell receptor and its uses in the detection, prevention and/or treatment of influenza
EP3137100B1 (en) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
MX375379B (en) * 2014-05-29 2025-03-06 Us Health Anti-human papillomavirus 16 e7 t cell receptors
SI3149480T1 (en) 2014-05-30 2019-05-31 Amgen Research (Munich) Gmbh Risk-stratification of b-precursor acute lymphoblastic leukemia patients
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
CN118994363A (en) * 2014-11-26 2024-11-22 美国卫生和人力服务部 Anti-mutated KRAS T cell receptor
EP4248744A3 (en) 2015-04-06 2023-12-27 Regeneron Pharmaceuticals, Inc. Humanized t cell mediated immune responses in non-human animals
EP3303392B1 (en) * 2015-06-01 2020-08-05 Medigene Immunotherapies GmbH Method for generating antibodies against t cell receptor
EA201792660A1 (en) 2015-06-01 2018-05-31 Медиджин Иммьюнотерапиз Гмбх T-CELL RECEPTOR LIBRARY
KR101794304B1 (en) * 2015-09-01 2017-11-06 가톨릭대학교 산학협력단 EBV antigen specific T-cell receptor and use thereof
US20190119350A1 (en) * 2015-09-09 2019-04-25 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
WO2017070042A1 (en) 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
MX2018004721A (en) 2015-10-23 2018-07-06 Eureka Therapeutics Inc CHEMICAL CONSTRUCTIONS ANTIBODY / T-CELL RECEIVER AND USES OF THE SAME.
WO2017076308A1 (en) * 2015-11-04 2017-05-11 广州市香雪制药股份有限公司 Tcr for identifying ny-eso-1 antigen oligopeptide
TWI752930B (en) 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 Novel generation of antigen-specific tcrs
ES2898329T3 (en) 2016-01-12 2022-03-07 Oncotracker Inc Improved methods for monitoring the immune status of a subject
CA3021898A1 (en) * 2016-04-26 2017-11-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-kk-lc-1 t cell receptors
US11827688B2 (en) 2016-06-02 2023-11-28 Immunocore Limited Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
US20190359678A1 (en) * 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
JP7538601B2 (en) 2017-04-26 2024-08-22 ユーリカ セラピューティックス， インコーポレイテッド Cells expressing chimeric activating and stimulating receptors and uses thereof - Patents.com
WO2018208553A1 (en) 2017-05-12 2018-11-15 Augusta University Research Institute, Inc. Human alpha fetoprotein-specific t cell receptors and uses thereof
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
KR20260026092A (en) 2017-09-19 2026-02-25 메사추세츠 인스티튜트 오브 테크놀로지 Compositions for chimeric antigen receptor t cell therapy and uses thereof
AU2018345400B2 (en) * 2017-10-05 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf Chimeric antigen receptors
US20200316122A1 (en) 2017-10-11 2020-10-08 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using p38 mapk inhibitors
KR20190076297A (en) 2017-12-22 2019-07-02 (주)메디톡스 MART-1 Specific T Cell Receptor and Use Thereof
EP3749770B9 (en) 2018-02-09 2025-12-17 The U.S.A. as represented by the Secretary, Department of Health and Human Services Tethered interleukin-15 and interleukin-21
CA3096458A1 (en) 2018-04-12 2019-10-17 Umoja Biopharma, Inc. Viral vectors and packaging cell lines
WO2019204683A1 (en) * 2018-04-19 2019-10-24 Board Of Regents, The University Of Texas System T cell receptors with mage-b2 specificity and uses thereof
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
AU2019302603A1 (en) * 2018-07-13 2021-01-14 Nanjing Legend Biotech Co., Ltd. Co-receptor systems for treating infectious diseases
CN110818802B (en) * 2018-08-08 2022-02-08 华夏英泰（北京）生物技术有限公司 Chimeric T cell receptor STAR and application thereof
AU2019372673A1 (en) 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
US20220017920A1 (en) 2018-11-21 2022-01-20 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
KR20200068263A (en) 2018-12-05 2020-06-15 (주)메디톡스 NY-ESO-1 Specific T Cell Receptor and Use Thereof
KR20210106437A (en) 2018-12-20 2021-08-30 노파르티스 아게 Dosage regimens and pharmaceutical combinations comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN113490528B (en) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020201527A1 (en) * 2019-04-04 2020-10-08 Umc Utrecht Holding B.V. Modified immune receptor constructs
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
BR112022011902A2 (en) 2019-12-20 2022-09-06 Novartis Ag COMBINATION THERAPIES
JP2023517063A (en) 2020-03-10 2023-04-21 マサチューセッツ インスティテュート オブ テクノロジー Methods and compositions for generating engineered memory-like NK cells
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
KR20230027056A (en) 2020-06-23 2023-02-27 노파르티스 아게 Dosage regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7819176B2 (en) 2020-08-03 2026-02-24 ノバルティス アーゲー Heteroaryl-substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2022055946A1 (en) 2020-09-08 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell phenotypes associated with response to adoptive cell therapy
US20240018210A1 (en) 2020-11-13 2024-01-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain
CN118511853A (en) 2021-03-31 2024-08-20 瑞泽恩制药公司 Genetically modified mice comprising humanized cellular immune system components with improved TCRB repertoire diversity
TW202304979A (en) 2021-04-07 2023-02-01 瑞士商諾華公司 USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES
JP2024525727A (en) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド Engineered T cell receptors fused to antibody-derived binding domains
WO2023002204A1 (en) * 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
US20250057949A1 (en) 2021-12-31 2025-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic T cell therapy with vaccination as a combination immunotherapy against cancer
WO2023131053A1 (en) * 2022-01-05 2023-07-13 苏州系统医学研究所 T cell receptor, and preparation method therefor and use thereof
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. Multipartite receptor and signaling complexes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074322A1 (en) * 2003-02-22 2004-09-02 Avidex Ltd Modified soluble t cell receptor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407221B1 (en) * 1990-12-14 2002-06-18 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
WO1992010591A1 (en) * 1990-12-14 1992-06-25 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
ATE546457T1 (en) * 1999-03-19 2012-03-15 Waldemar Priebe METHOD AND COMPOSITIONS FOR PRODUCING C-3' AND C-4' ANTHRACYCLINE ANTIBIOTICS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074322A1 (en) * 2003-02-22 2004-09-02 Avidex Ltd Modified soluble t cell receptor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOULTER JONATHAN M ET AL: "Stable, soluble T-cell receptor molecules for crystallization and therapeutics", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 16, no. 9, September 2003 (2003-09-01), pages 707 - 711, XP002275339, ISSN: 0269-2139 *
CHANG H-C ET AL: "A GENERAL METHOD FOR FACILITATING HETERODIMERIC PAIRING BETWEEN TWO PROTEINS: APPLICATION TO EXPRESSION OF ALPHA AND BETA T-CELL RECEPTOR EXTRACELLULAR SEGMENTS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 91, no. 24, November 1994 (1994-11-01), pages 11408 - 11412, XP002008362, ISSN: 0027-8424 *
COHEN CYRILLE J ET AL: "Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.", CANCER RESEARCH 1 SEP 2006, vol. 66, no. 17, 1 September 2006 (2006-09-01), pages 8878 - 8886, XP002466475, ISSN: 1538-7445 *
COHEN CYRILLE J ET AL: "Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR", JOURNAL OF IMMUNOLOGY, vol. 175, no. 9, November 2005 (2005-11-01), pages 5799 - 5808, XP002466476, ISSN: 0022-1767 *
KUBALL J ET AL: "Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR", IMMUNITY, CELL PRESS, US, vol. 22, no. 1, January 2005 (2005-01-01), pages 117 - 129, XP002351551, ISSN: 1074-7613 *
WILLEMSEN R A ET AL: "GRAFTING PRIMARY HUMAN T LYMPHOCYTES WITH CANCER-SPECIFIC CHIMERIC SINGLE CHAIN AND TWO CHAIN TCR", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 7, no. 16, August 2000 (2000-08-01), pages 1369 - 1377, XP001181298, ISSN: 0969-7128 *
ZHAO ET AL: "High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 13, no. 1, January 2006 (2006-01-01), pages 151 - 159, XP005197704, ISSN: 1525-0016 *

Also Published As

Publication number Publication date
DK2016102T3 (en) 2012-07-02
WO2007131092A2 (en) 2007-11-15
AU2007248019A1 (en) 2007-11-15
CA2651174A1 (en) 2007-11-15
ATE550356T1 (en) 2012-04-15
EP2016102A2 (en) 2009-01-21
AU2007248019B2 (en) 2012-10-11
EP2016102B1 (en) 2012-03-21
US20130116167A1 (en) 2013-05-09
ES2382777T3 (en) 2012-06-13
US20090304657A1 (en) 2009-12-10
PT2016102E (en) 2012-05-15

Similar Documents

Publication Publication Date Title
WO2007131092A3 (en) Chimeric t cell receptors and related materials and methods of use
UA107921C2 (en) Variants of polypeptide of receptor ivr activin and their use
WO2005121331A8 (en) Truncated galnact2 polypeptides and nucleic acids
WO2010042890A3 (en) Polypeptides that bind trail-ri and trail-r2
EP1994157A4 (en) RECOMBINANT HUMAN EPO-FC FUSION PROTEINS HAVING EXTENDED HALF-LIFE AND INCREASED ERYTHROPOIETIC ACTIVITY IN VIVO
WO2008080042A3 (en) Use of long-acting glp-1 receptor agonists to improve insulin sensitivity and lipid profiles
WO2005121332A3 (en) Truncated st6galnaci polypeptides and nucleic acids
PH12012502272A1 (en) Biological materials related to her3
IL181839A0 (en) Fusion proteins and pharmaceutical compositions containing the same
WO2008011120A3 (en) Human endogenous retrovirus polypeptide compositions and methods of use thereof
WO2008074839A3 (en) Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
WO2001066753A3 (en) Human genes and gene expression products
WO2009001260A3 (en) Cosmetic use of apolipoprotein d type proteins
WO2002014500A3 (en) Human genes and gene expression products
EA200601738A1 (en) MODIFIED PROTEINS OF BOUGHINE, CYTOTOXINES AND METHODS OF THEIR APPLICATION
BRPI0817026A2 (en) nucleic acid molecule, isolated polypeptide, fusion polypeptide, genetic construct, methods for producing an avian recombinant interferon-lambda molecule in a cell, for identifying an avian interferon-lambda gene sequence, for positively inducing or regulating a response avian interferon-lambda molecule, isolated cell, antibody molecule, computer readable medium, assay for measuring the level of an avian interferon-lambda polypeptide in birds, use of the avian interferon-lambda polypeptide or nucleic acid molecule, adjuvant medicinal or therapeutic foodstuff, and veterinary pharmaceutical composition.
WO2004045544A3 (en) Autocrine growth factor receptor antibodies and methods
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2005111204A3 (en) Porcine forssman synthetase cdna and polypeptide
WO2005079367A3 (en) Schizochytrium fatty acid synthase (fas) and products and methods related thereto
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
WO2007075899A8 (en) Dual agonist compounds and uses thereof
BR112013022557A2 (en) peptide binders polypeptide compositions and methods for using them
WO2007051063A3 (en) Gpcr expressing cell lines and antibodies
WO2008062158A3 (en) Polypeptide monomers and dimers containing mutated ilt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07797329

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007248019

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2651174

Country of ref document: CA

Ref document number: 2007797329

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007248019

Country of ref document: AU

Date of ref document: 20070503

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12298927

Country of ref document: US